Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
266 articles
New research reveals fatty liver disease follows circadian patterns linked to insulin resistance and reduced nighttime insulin availability.
FDA approves Foundayo (orforglipron) and Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight conditions.
New research reveals how glucose metabolism directly controls fat tissue expansion through a novel epigenetic pathway involving JMJD1A.
Scientists discover how FGF21 fights liver disease through a key protein, opening new treatment paths for metabolic dysfunction.
Large-scale study identifies three key blood proteins that predict diabetic retinopathy development with 90% accuracy.
Large NHANES study reveals metabolic syndrome causes measurable acceleration in epigenetic aging clocks, offering new targets for intervention.
FDA-integrated CGMs provide superior accuracy and safety compared to non-approved devices flooding global markets.
Meta-analysis of 106,395 patients reveals GLP-1 receptor agonists increase risk of gallstones by 46% and GERD by 119%.
New research reveals how obesity triggers chronic inflammation and how GLP-1 medications provide anti-inflammatory benefits independent of weight loss.
New research explores how GLP-1-based drugs like Ozempic and Wegovy work to treat obesity beyond simple appetite suppression.
Researchers discover how disrupted circadian rhythms in fat cells impair mitochondrial function, leading to metabolic syndrome.
Machine learning analyzes glucose patterns to identify distinct metabolic subphenotypes in type 2 diabetes patients.
